Welcome, ladies and gentlemen, to AstraZeneca's full-year and Q4 2024 results conference call for investors and analysts. Before I hand over to AstraZeneca, I'd like to read the safe harbor statement.

CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary Financial performance for FY 2024 (Growth numbers at constant exchange rates) Total Revenue up 21% to $54,073m ...

Reports Q4 revenue $1.99M vs $33.22M last year. “2024 has been an important year for Cellectis (CLLS): we are now developing three programs in ...

Baker Brothers' 13F portfolio value decreased from $9.65B to $9.36B. Check out the portfolio's top holdings and notable stake ...

AstraZeneca PLC beat Q4 and full-year 2024 earnings estimates, with significant revenue and EPS growth, and forecasts further growth in 2025 despite China-related setbacks. The company faces ...

Reports Q4 revenue $14.89B, consensus $13.34B. The company said, “Our company delivered a very strong performance in 2024 with Total ... Read More on AZN: AstraZeneca NewsMORE Related Stocks ...

Compugen Ltd (CGEN) showcases promising developments in oncology treatments while navigating a decrease in annual revenue and ...

AstraZeneca PLC (NASDAQ:AZN) is facing ongoing investigations in China regarding suspected unpaid importation taxes, which could result in significant fines. The company experienced a 3% decline in Q4 ...

AstraZeneca PLC (NASDAQ:AZN) Q4 2024 Earnings Call Transcript February 6, 2025 AstraZeneca PLC misses on earnings expectations. Reported EPS is $1.05 EPS, expectations were $1.07. Pascal Soriot ...